Evidence map›Paper›PMID 34547582›Full record

ArticleComputers in biology and medicine2021

Artificial intelligence approach towards assessment of condition of COVID-19 patients - Identification of predictive biomarkers associated with severity of clinical condition and disease progression.

Anđela Blagojević, Tijana Šušteršič, Ivan Lorencin, Sandi Baressi Šegota, Nikola Anđelić, Dragan Milovanović, Danijela Baskić, Dejan Baskić, Nataša Zdravković Petrović, Predrag Sazdanović and 2 more

Abstract read
In one paragraph

Article in Computers in biology and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anđela BlagojevićUniversity of Kragujevac, Faculty of Engineering, Sestre Janjić 6, 34000, Kragujevac, Serbia; Bioengineering Research and Development Center (BioIRC), Prvoslava Stojanovića 6, 34000, Kragujevac, Serbia. Electronic address: andjela.blagojevic@kg.ac.rs.
Tijana ŠušteršičUniversity of Kragujevac, Faculty of Engineering, Sestre Janjić 6, 34000, Kragujevac, Serbia; Bioengineering Research and Development Center (BioIRC), Prvoslava Stojanovića 6, 34000, Kragujevac, Serbia. Electronic address: tijanas@kg.ac.rs.
Ivan LorencinUniversity of Rijeka, Faculty of Engineering, Vukovarska 58, 51000, Rijeka, Croatia. Electronic address: ilorencin@riteh.hr.
Sandi Baressi ŠegotaUniversity of Rijeka, Faculty of Engineering, Vukovarska 58, 51000, Rijeka, Croatia. Electronic address: sbaressisegota@riteh.hr.
Nikola AnđelićUniversity of Rijeka, Faculty of Engineering, Vukovarska 58, 51000, Rijeka, Croatia. Electronic address: nandelic@riteh.hr.
Dragan MilovanovićClinical Centre Kragujevac, Zmaj Jovina 30, 34000, Kragujevac, Serbia; University of Kragujevac, Faculty of Medical Sciences, Svetozara Markovića 69, 34000, Kragujevac, Serbia. Electronic address: piki@medf.kg.ac.rs.
Danijela BaskićClinical Centre Kragujevac, Zmaj Jovina 30, 34000, Kragujevac, Serbia. Electronic address: d.baskic@gmail.com.
Dejan BaskićUniversity of Kragujevac, Faculty of Medical Sciences, Svetozara Markovića 69, 34000, Kragujevac, Serbia; Institute of Public Health Kragujevac, Nikole Pašića 1, 34000, Kragujevac, Serbia. Electronic address: dejan.baskic@gmail.com.
Nataša Zdravković PetrovićClinical Centre Kragujevac, Zmaj Jovina 30, 34000, Kragujevac, Serbia; University of Kragujevac, Faculty of Medical Sciences, Svetozara Markovića 69, 34000, Kragujevac, Serbia. Electronic address: silvester@sbb.com.
Predrag SazdanovićClinical Centre Kragujevac, Zmaj Jovina 30, 34000, Kragujevac, Serbia; University of Kragujevac, Faculty of Medical Sciences, Svetozara Markovića 69, 34000, Kragujevac, Serbia. Electronic address: predrag.sazdanovic@gmail.com.
Zlatan CarUniversity of Rijeka, Faculty of Engineering, Vukovarska 58, 51000, Rijeka, Croatia. Electronic address: car@riteh.hr.
Nenad FilipovićUniversity of Kragujevac, Faculty of Engineering, Sestre Janjić 6, 34000, Kragujevac, Serbia; Bioengineering Research and Development Center (BioIRC), Prvoslava Stojanovića 6, 34000, Kragujevac, Serbia. Electronic address: fica@kg.ac.rs.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesAlthough ML has been studied for different epidemiological and clinical issues as well as for survival prediction of COVID-19, there is a noticeable shortage of literature dealing with ML usage in prediction of disease severity changes through the course of the disease. In that way, predicting disease progression from mild towards moderate, severe and critical condition, would help not only to respond in a timely manner to prevent lethal results, but also to minimize the number of patients in hospitals where this is not necessary.

methodsWe present a methodology for the classification of patients into 4 distinct categories of the clinical condition of COVID-19 disease. Classification of patients is based on the values of blood biomarkers that were assessed by Gradient boosting regressor and which were selected as biomarkers that have the greatest influence in the classification of patients with COVID-19.

resultsThe results show that among several tested algorithms, XGBoost classifier achieved best results with an average accuracy of 94% and an average F1-score of 94.3%. We have also extracted 10 best features from blood analysis that are strongly associated with patient condition and based on those features we can predict the severity of the clinical condition.

conclusionsThe main advantage of our system is that it is a decision tree-based algorithm which is easier to interpret, instead of the use of black box models, which are not appealing in medical practice.

Indexed as

Artificial IntelligenceCOVID-19BiomarkersDisease ProgressionHumansMachine LearningSARS-CoV-2BiomarkersClinical condition assessmentCOVID-19Personalized modelPredictive blood biomarkersRule-based machine learning

Identifiers

PMID34547582
PMCPMC8438805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.